Healthcare Roundup – AstraZeneca’s Calquence flunks mid-stage COVID-19 study; Biocept +4% on COVID-19 testing update

Published on: November 12, 2020
Author: Amy Liu

AstraZeneca’s Calquence flunks mid-stage COVID-19 study

AstraZeneca (NASDAQ:AZN) reports Phase II results from The CALAVI trials investigating BTK inhibitor Calquence (acalabrutinib) plus best supportive care (BSC) versus BSC alone in hospitalised patients with COVID-19 disease.

Calquence did not meet the primary efficacy endpoint. The addition of Calquence to BSC did not increase the proportion of patients who remained alive and free of respiratory failure.

No new safety signal was observed in the trials.

The safety and tolerability profiles for Calquence in the CALAVI program were consistent with previous trials.

The data will be presented in due course.

Biocept +4% on COVID-19 testing update

Biocept (NASDAQ:BIOC) provides an update on its COVID-19 testing with more than 100,000 samples received to date for processing through its RT-PCR technology.

The company provides COVID-19 test results within 48 hours of receiving a sample.

BIOC is providing COVID-19 testing to skilled nursing centers, hospitals, clinics and surgery centers.

“We expect COVID-19 RT-PCR testing will have a significant positive impact on our revenues through the remainder of the year and continuing into 2021,” said Michael Nall, President and CEO.

Shares up 4% premarket.

VolitionRX EPS beats by $0.02

VolitionRX (NYSEMKT:VNRX): Q3 GAAP EPS of -$0.09 beats by $0.02.

Revenue of $575 vs. $17.1K

Ovid Therapeutics EPS beats by $0.14, beats on revenue

Ovid Therapeutics (NASDAQ:OVID): Q3 GAAP EPS of -$0.28 beats by $0.14.

Revenue of $6.9M beats by $6.82M.

Cash and cash equivalents of $86.9M.

Shares -2.4%.

Akero Therapeutics EPS beats by $0.03

Akero Therapeutics (NASDAQ:AKRO): Q3 GAAP EPS of -$0.63 beats by $0.03.

Cash, cash equivalents and short-term marketable securities of $291.9M.

Biotechnology COVID-19 Healthcare Services Life Science